This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases compared two treatments for late-onset Pompe disease, a rare hereditary condition with severe symptoms affecting daily life. The research found that patients receiving avalglucosidase alfa reported more significant improvements than those receiving alglucosidase alfa across multiple areas: breathing ability, morning headaches, movement, overall physical and mental health, daily functions (including fatigue, pain, anxiety, depression, self-care, and daily activities), and selected activities.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial’ and was published in Molecular Genetics and Metabolism. 

Visit Elsevier using the link to read the original article.